Keystone Nano wins FDA nod for nanoliposome cancer treatment

Keystone Nano said today that the FDA approved its investigational new drug application for the ceramide nanoliposome as a treatment for solid tumors. The company will launch a phase I trial at 3 sites to evaluate safe dosing levels and the product’s efficacy as a cancer therapy. Ceramide is a lipid that has demonstrated efficacy in liver cancer, breast cancer, leukemia and pancreatic cancer. Preclinical evidence has shown that Keystone’s nanoliposome is an effective delivery system for the bioactive compound, targeting cancer cells and ignoring healthy cells. Get the full story at our sister site, Drug Delivery Business News. The post Keystone Nano wins FDA nod for nanoliposome cancer treatment appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Drug-Device Combinations Food & Drug Administration (FDA) Oncology Pharmaceuticals Regulatory/Clearance Wall Street Beat Keystone Nano Source Type: news